Financhill
Sell
46

ACLX Quote, Financials, Valuation and Earnings

Last price:
$58.39
Seasonality move :
35.84%
Day range:
$56.81 - $59.81
52-week range:
$47.86 - $107.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
41.24x
P/B ratio:
7.73x
Volume:
912.2K
Avg. volume:
838.6K
1-year change:
13.01%
Market cap:
$3.2B
Revenue:
$107.9M
EPS (TTM):
-$2.99

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ACLX
Arcellx
$19.5M -$0.74 -53% -107.65% $111.53
ATNM
Actinium Pharmaceuticals
-- -$0.28 -100% -7.24% $5.00
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
NNVC
Nanoviricides
-- -$0.20 -- -26.67% --
OGEN
Oragenics
-- -- -- -- $1.00
TOVX
Theriva Biologics
-- -$1.56 -- -8.25% $7.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ACLX
Arcellx
$58.45 $111.53 $3.2B -- $0.00 0% 41.24x
ATNM
Actinium Pharmaceuticals
$1.53 $5.00 $47.7M -- $0.00 0% --
NBY
NovaBay Pharmaceuticals
$0.58 $0.85 $3.4M -- $0.00 0% 0.16x
NNVC
Nanoviricides
$1.31 -- $20.5M -- $0.00 0% --
OGEN
Oragenics
$0.19 $1.00 $4.2M -- $0.00 0% 1.21x
TOVX
Theriva Biologics
$0.57 $7.00 $1.6M -- $0.00 0% 0.63x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ACLX
Arcellx
-- 1.028 -- 4.83x
ATNM
Actinium Pharmaceuticals
-- -3.541 -- 9.03x
NBY
NovaBay Pharmaceuticals
4.54% -0.186 1.51% 0.75x
NNVC
Nanoviricides
-- 2.080 -- --
OGEN
Oragenics
-- 3.254 -- --
TOVX
Theriva Biologics
-- -2.512 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ACLX
Arcellx
-- -$68.9M -34.73% -34.73% -765.88% -$63.9M
ATNM
Actinium Pharmaceuticals
-- -$16.6M -95.08% -95.08% -12769.14% -$7.6M
NBY
NovaBay Pharmaceuticals
$1.6M -$1.1M -334.47% -461.38% -44% -$2.1M
NNVC
Nanoviricides
-- -$2.1M -- -- -- -$2.2M
OGEN
Oragenics
-- -$3.4M -- -- -- -$2M
TOVX
Theriva Biologics
-- -$4.6M -- -- -- -$4.7M

Arcellx vs. Competitors

  • Which has Higher Returns ACLX or ATNM?

    Actinium Pharmaceuticals has a net margin of -766.02% compared to Arcellx's net margin of -11511.11%. Arcellx's return on equity of -34.73% beat Actinium Pharmaceuticals's return on equity of -95.08%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    ATNM
    Actinium Pharmaceuticals
    -- -$0.51 $36.4M
  • What do Analysts Say About ACLX or ATNM?

    Arcellx has a consensus price target of $111.53, signalling upside risk potential of 90.82%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 226.8%. Given that Actinium Pharmaceuticals has higher upside potential than Arcellx, analysts believe Actinium Pharmaceuticals is more attractive than Arcellx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    12 0 0
    ATNM
    Actinium Pharmaceuticals
    2 1 0
  • Is ACLX or ATNM More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.236, suggesting its less volatile than the S&P 500 by 123.637%.

  • Which is a Better Dividend Stock ACLX or ATNM?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or ATNM?

    Arcellx quarterly revenues are $8.1M, which are larger than Actinium Pharmaceuticals quarterly revenues of $81K. Arcellx's net income of -$62.3M is lower than Actinium Pharmaceuticals's net income of -$15.9M. Notably, Arcellx's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 41.24x versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    41.24x -- $8.1M -$62.3M
    ATNM
    Actinium Pharmaceuticals
    -- -- $81K -$15.9M
  • Which has Higher Returns ACLX or NBY?

    NovaBay Pharmaceuticals has a net margin of -766.02% compared to Arcellx's net margin of -49.65%. Arcellx's return on equity of -34.73% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    NBY
    NovaBay Pharmaceuticals
    65.26% -$0.60 $1.1M
  • What do Analysts Say About ACLX or NBY?

    Arcellx has a consensus price target of $111.53, signalling upside risk potential of 90.82%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that Arcellx has higher upside potential than NovaBay Pharmaceuticals, analysts believe Arcellx is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    12 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is ACLX or NBY More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.419, suggesting its less volatile than the S&P 500 by 58.08%.

  • Which is a Better Dividend Stock ACLX or NBY?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or NBY?

    Arcellx quarterly revenues are $8.1M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Arcellx's net income of -$62.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Arcellx's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 41.24x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    41.24x -- $8.1M -$62.3M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M -$1.2M
  • Which has Higher Returns ACLX or NNVC?

    Nanoviricides has a net margin of -766.02% compared to Arcellx's net margin of --. Arcellx's return on equity of -34.73% beat Nanoviricides's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    NNVC
    Nanoviricides
    -- -$0.14 --
  • What do Analysts Say About ACLX or NNVC?

    Arcellx has a consensus price target of $111.53, signalling upside risk potential of 90.82%. On the other hand Nanoviricides has an analysts' consensus of -- which suggests that it could grow by 396.18%. Given that Nanoviricides has higher upside potential than Arcellx, analysts believe Nanoviricides is more attractive than Arcellx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    12 0 0
    NNVC
    Nanoviricides
    0 0 0
  • Is ACLX or NNVC More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nanoviricides has a beta of 0.947, suggesting its less volatile than the S&P 500 by 5.32%.

  • Which is a Better Dividend Stock ACLX or NNVC?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nanoviricides offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Nanoviricides pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or NNVC?

    Arcellx quarterly revenues are $8.1M, which are larger than Nanoviricides quarterly revenues of --. Arcellx's net income of -$62.3M is lower than Nanoviricides's net income of -$2M. Notably, Arcellx's price-to-earnings ratio is -- while Nanoviricides's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 41.24x versus -- for Nanoviricides. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    41.24x -- $8.1M -$62.3M
    NNVC
    Nanoviricides
    -- -- -- -$2M
  • Which has Higher Returns ACLX or OGEN?

    Oragenics has a net margin of -766.02% compared to Arcellx's net margin of --. Arcellx's return on equity of -34.73% beat Oragenics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    OGEN
    Oragenics
    -- -$0.27 --
  • What do Analysts Say About ACLX or OGEN?

    Arcellx has a consensus price target of $111.53, signalling upside risk potential of 90.82%. On the other hand Oragenics has an analysts' consensus of $1.00 which suggests that it could grow by 413.88%. Given that Oragenics has higher upside potential than Arcellx, analysts believe Oragenics is more attractive than Arcellx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    12 0 0
    OGEN
    Oragenics
    0 1 0
  • Is ACLX or OGEN More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Oragenics has a beta of 1.161, suggesting its more volatile than the S&P 500 by 16.138%.

  • Which is a Better Dividend Stock ACLX or OGEN?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or OGEN?

    Arcellx quarterly revenues are $8.1M, which are larger than Oragenics quarterly revenues of --. Arcellx's net income of -$62.3M is lower than Oragenics's net income of -$3.3M. Notably, Arcellx's price-to-earnings ratio is -- while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 41.24x versus 1.21x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    41.24x -- $8.1M -$62.3M
    OGEN
    Oragenics
    1.21x -- -- -$3.3M
  • Which has Higher Returns ACLX or TOVX?

    Theriva Biologics has a net margin of -766.02% compared to Arcellx's net margin of --. Arcellx's return on equity of -34.73% beat Theriva Biologics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ACLX
    Arcellx
    -- -$1.13 $416.9M
    TOVX
    Theriva Biologics
    -- -$1.60 --
  • What do Analysts Say About ACLX or TOVX?

    Arcellx has a consensus price target of $111.53, signalling upside risk potential of 90.82%. On the other hand Theriva Biologics has an analysts' consensus of $7.00 which suggests that it could grow by 1134.13%. Given that Theriva Biologics has higher upside potential than Arcellx, analysts believe Theriva Biologics is more attractive than Arcellx.

    Company Buy Ratings Hold Ratings Sell Ratings
    ACLX
    Arcellx
    12 0 0
    TOVX
    Theriva Biologics
    1 1 0
  • Is ACLX or TOVX More Risky?

    Arcellx has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.144, suggesting its more volatile than the S&P 500 by 14.418%.

  • Which is a Better Dividend Stock ACLX or TOVX?

    Arcellx has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcellx pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ACLX or TOVX?

    Arcellx quarterly revenues are $8.1M, which are larger than Theriva Biologics quarterly revenues of --. Arcellx's net income of -$62.3M is lower than Theriva Biologics's net income of -$4.4M. Notably, Arcellx's price-to-earnings ratio is -- while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcellx is 41.24x versus 0.63x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ACLX
    Arcellx
    41.24x -- $8.1M -$62.3M
    TOVX
    Theriva Biologics
    0.63x -- -- -$4.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Uber Stock 5X?
Will Uber Stock 5X?

Uber (NYSE:UBER) has generated extremely strong returns for its investors…

How High Will Bloom Energy Stock Go?
How High Will Bloom Energy Stock Go?

Bloom Energy (NYSE:BE) has seen its shares surge by more…

Is Acuity a Good Stock to Buy Now?
Is Acuity a Good Stock to Buy Now?

Acuity Brands (NYSE:AYI) is an industrial company specializing in lighting.…

Stock Ideas

Buy
70
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 38x

Buy
71
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
59
RGC alert for May 16

Regencell Bioscience Holdings [RGC] is up 16.91% over the past day.

Buy
89
BOOT alert for May 16

Boot Barn Holdings [BOOT] is up 16.55% over the past day.

Sell
43
FI alert for May 16

Fiserv [FI] is down 16.2% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock